Dorian Technologies offers DOlab, a cross‑platform desktop application that automates quantitative analysis of PET, SPECT, and MRI neuroimaging biomarkers using AI‑driven segmentation, radiomics, and tracer‑kinetic modeling. The cloud‑backed workflow generates HIPAA‑compliant reports with normative comparisons, age‑adjusted percentiles, and probabilistic diagnostic scores that can be integrated into radiology or EHR systems.
Funding
Funding not disclosed
Founders
Product
Problem
Clinicians and researchers often lack access to standardized, high‑throughput quantitative analysis tools for neuroimaging biomarkers, leading to inconsistent diagnostic interpretation and delayed detection of neurodegenerative diseases such as Alzheimer’s. Existing workflows require specialized hardware and manual processing, creating a gap between research‑grade analytics and routine clinical practice.
Solution
Dorian Technologies delivers the DOlab platform—a cross‑platform desktop application that automates the quantification of PET, SPECT, and MRI biomarkers using AI‑driven algorithms. Users upload raw imaging data, the system performs cloud‑backed high‑performance processing, and returns a downloadable report enriched with normative comparisons and age‑adjusted percentiles. Integrated patented radiomic methods (ELBA) and tracer‑kinetic modeling (TDR) enhance accuracy for amyloid PET, while machine‑learning classifiers provide probabilistic assessments for DAT‑SPECT and FDG‑PET studies. The platform also offers DOstat for customized data collection and analytics, and DOlearn to train clinicians on quantitative imaging workflows. All results are delivered in a secure, HIPAA‑compliant format that can be incorporated into existing radiology or electronic health record systems, thereby bridging the research‑clinical divide.
Target Audience
Primary customers are neurologists, nuclear medicine physicians, radiologists, and research teams in academic hospitals or biotech firms that require quantitative neuroimaging biomarkers for diagnosis, trial enrollment, and therapeutic monitoring.
Features
- AI‑powered segmentation and radiomic analysis (ELBA) that extracts whole‑brain intensity patterns without requiring reference regions
- Tracer‑kinetic target detection (TDR) for amyloid PET, delivering robust quantification across all commercial tracers
- Automated computation of DAT‑SPECT markers (PD, Vol, SBR, shape) with age‑corrected percentile outputs and a machine‑learning probabilistic diagnostic score
- Optimized FDG‑PET processing using SPM‑based pipelines to improve early neurodegeneration detection
- 3D T1‑weighted MRI atrophy assessment with localized medial temporal lobe ROI analysis and two‑year conversion risk index
- Upload‑process‑download workflow that eliminates the need for on‑site high‑performance hardware, leveraging cloud compute resources
- Comprehensive, exportable PDF/HTML reports with clinical annotations, normative database comparisons, and API hooks for EHR/FHIR integration
- DOstat customizable analytics suite for health services and research institutions, plus DOlearn interactive training modules for clinicians